Hepatitis B Human Immunoglobulin

[Clinical pharmacology]

Hepatitis B Human Immunoglobulin is derived from human plasma containing highly potent hepatitis B surface antibodies, which can specifically bind to and clear the travelling hepatitis B virus, and can provide passive immunity, and has the effect of enhancing the body's immune function against the hepatitis B virus. Hepatitis B human immunoglobulin injection can provide passive immunological protection for HBV-infected patients before the active immunity of hepatitis B vaccine has been produced.

The half-life of hepatitis B immunoglobulin in the human body is 17.5-25 days. In general, after injection of 100-200 IU/ml of hepatitis B human immunoglobulin, the serum surface antibody against hepatitis B (anti-H-Bs) can be up to 38.9%, and 41.7% at 7 days, and a certain level can be maintained for 12 months after repeated injections in general. Levels.